Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

DoctorAdam vs NextMeds

DoctorAdam
Graded #54

Higher grade

vs+9.600000000000009
NextMeds
Graded #191

Lower grade

The verdict

DoctorAdam takes it — 75.9/100 to 66.3/100.

DoctorAdam grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. DoctorAdam is a Shopify-based telehealth platform offering compounded semaglutide and tirzepatide in both injection and oral tablet forms, with flat all-in monthly pricing covering physician evaluation,…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueDoctorAdam +22
78
56
Dose & formulationDoctorAdam +24
88
64
Clinical oversightDoctorAdam +8
85
77
Labs & monitoringNextMeds +8
53
61
FulfillmentNextMeds +5
79
84
Contract termsNextMeds +6
55
61
DoctorAdam · left barNextMeds · right bar

The numbers

MetricDoctorAdamNextMeds
WeighScore75.9/10066.3/100
GradeCC
Scorecard rank#54#191
Semaglutide$129/mo (starting dose, compounded)$129/mo (plus a separate fee, compounded)
Tirzepatide$229/mo (starting dose, compounded)$179/mo (plus a separate fee, compounded)
Coverage44 statesAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
DoctorAdam

Graded #54 · C

Strengths

  • Offers both injection and oral tablet forms of compounded semaglutide and tirzepatide
  • Flat all-in pricing — physician evaluation, medication, and free shipping included
  • Named pharmacy partners: Olympia Pharmaceuticals (Orlando, FL) and Carie Boyd Pharmaceuticals (Irving, TX)
  • LegitScript certified with 4.8/5 Trustpilot score from 5,400+ reviews and 100K+ patients
  • No hidden fees, no required recurring commitment, full refund if not prescribed

Where it loses points

  • Compounded medications are not FDA-approved individual drugs
  • No labs or dedicated coaching disclosed on public pages
  • Only 44 states served — AK, MA, MS, NJ, RI, and VT excluded despite homepage '50 states' claim
  • Dose-tier pricing not published; only starting prices visible without quiz
  • Shopify-based store rather than a dedicated health platform
NextMeds

Graded #191 · C

Strengths

  • Flat monthly membership bundles the medication, telehealth visits, a 1:1 care coach and a licensed registered dietitian — one price, no hidden fees
  • Same price every dose, no auto-renewal, cancel anytime; free shipping and no insurance needed (FSA eligible)
  • Names a compounding pharmacy partner (Foothills Pharmacy) and states it services all 50 states
  • Free, no-obligation online assessment before you pay anything

Where it loses points

  • Shows a LegitScript 'approval' but links only a generic directory search, not a verifiable seal — we couldn't independently confirm it
  • Promo-driven pricing with a countdown timer and 'price increases' urgency; the standing membership is $129 (sema) / $179 (tirz)
  • A technology platform that coordinates care, not the medical provider; individual clinicians and a medical director aren't named on the site
  • Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard